Showing results 1 to 1 of 1
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
380MO A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure Proceeding/Conference:Annals of Oncology | 2020 | 7 |